Advertisement

Dopamine Injection

[02 December 2014]

Products Affected - Description

Dopamine injection, American Regent
40 mg/mL, 5 mL vial (NDC 00517-1805-25)
80 mg/mL, 5 mL vial (NDC 00517-1905-25)
160 mg/mL, 5 mL vial (NDC 00517-1305-25)
 
Dopamine in Dextrose 5% Injection, Hospira
200 mg/250 mL (NDC 00409-7808-22)
400 mg/500 mL (NDC 00409-7808-24)
400 mg/250 mL (NDC 00409-7809-22)

Reason for the Shortage

  • B Braun discontinued their dopamine premix in November 2012 due to raw material supply issues.
  • Hospira states the shortage is due to manufacturing delays.
  • American Regent has recently upgraded their manufacturing plant. Product will become available in stages as production resumes.
  • Baxter had dopamine on allocation due to increased demand.

Available Products

Dopamine in Dextrose 5% Injection, Baxter
200 mg/250 mL (NDC 00338-1005-02)
400 mg/250 mL (NDC 00338-1007-02)
400 mg/500 mL (NDC 00338-1005-03)
800 mg/500 mL (NDC 00338-1007-03)
800 mg/250 mL (NDC 00338-1009-02)
 
Dopamine Injection, Hospira
40 mg/mL, 5 mL vial (NDC 00409-5820-01)
40 mg/mL, 10 mL vial (NDC 00409-9104-20)
 
Dopamine in Dextrose 5% Injection, Hospira
800 mg/250 mL (NDC 00409-7810-22)
800 mg/500 mL (NDC 00409-7809-24)

Estimated Resupply Dates

  • American Regent has all dopamine presentations on back order and the company cannot estimate a release date.
  • Hospira has dopamine 200 mg/250 mL, 400 mg/250 mL, and 400 mg/500 mL premixes on back order with an estimated release date of December 2014.

Related Shortages

Updated

December 2, 2014; November 20, 2014; October 24, 2014; October 2, 2014; September 11, 2014; August 15, 2014; July 11, 2014; June 23, 2014; May 22, 2014; April 16, 2014; March 7, 2014; February 5, 2014; January 8, 2014; December 9, 2013; November 13, 2013; November 12, 2013; November 4, 2013; October 21, 2013; October 14, 2013; September 5, 2013; June 28, 2013; June 19, 2013; May 13, 2013; April 1, 2013; March 14, 2013; February 13, 2013; January 23, 2013; January 4, 2013; November 14, 2012; October 31, 2012; September 7, 2012; July 26, 2012; June 12, 2012; April 4, 2012; March 22, 2012; February 24, 2012; January 31, 2012; January 10, 2012; December 29, 2011; November 17, 2011; October 31, 2011; September 20, 2011; August 31, 2011; July 22, 2011; July 1, 2011; May 23, 2011; May 6, 2011; April 27, 2011; March 21, 2011; July 11, 2006; June 5, 2006, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement